Back to Search
Start Over
GMP prevents excitotoxicity mediated by NMDA receptor activation but not by reversal activity of glutamate transporters in rat hippocampal slices.
- Source :
-
Brain research [Brain Res] 2008 Sep 22; Vol. 1231, pp. 113-20. Date of Electronic Publication: 2008 Jul 11. - Publication Year :
- 2008
-
Abstract
- Glutamate is the main excitatory neurotransmitter in the mammalian nervous system and is essential for its normal functions. However, overstimulation of glutamatergic system due to hyperactivation of NMDA receptors and/or impairment of glutamate reuptake system has been implicated in many acute and chronic neurological diseases. Regulation of extracellular glutamate concentrations relies on the function of glutamate transporters which can be reversed in situations related to excitotoxicity. Guanosine-5'-monophosphate (GMP), a guanine nucleotide which displays important extracellular roles, such as trophic effects to neurons and astrocytes, behaves as antagonist of glutamate receptors and is neuroprotective in hippocampal slices against excitotoxicity or ischemic conditions. Hippocampal slices exposed to 1 or 10 mM glutamate, or 100 microM NMDA with 10 microM glycine for 1 h and evaluated after 6 or 18 h, showed reduced cell viability and DNA fragmentation, respectively. Glutamate- or NMDA-induced cell death was prevented by 50 microM MK-801, but only NMDA-induced cell damage was prevented by GMP (1 mM). Glutamate-induced cell viability impairment and glutamate-induced l-[(3)H]glutamate release were both prevented by adding DL-TBOA (10 microM). Otherwise, NMDA-induced cell viability loss was not prevented by 10 microM of DL-TBOA and NMDA did not induce l-[(3)H]glutamate release. Our results demonstrate that GMP is neuroprotective when acting selectively at NMDA receptors. Glutamate-induced hippocampal slice damage and glutamate release were blocked by glutamate transporter inhibitor, indicating that glutamate-induced toxicity also involves the reversal of glutamate uptake, which cannot be prevented by GMP.
- Subjects :
- Animals
Aspartic Acid pharmacology
Brain Diseases, Metabolic drug therapy
Brain Diseases, Metabolic metabolism
Brain Diseases, Metabolic physiopathology
Cell Survival drug effects
Cell Survival physiology
DNA Fragmentation drug effects
Dose-Response Relationship, Drug
Excitatory Amino Acid Agonists pharmacology
Excitatory Amino Acid Antagonists pharmacology
Glutamic Acid toxicity
Guanosine Monophosphate therapeutic use
Hippocampus metabolism
Hippocampus physiopathology
Male
N-Methylaspartate antagonists & inhibitors
N-Methylaspartate toxicity
Neuroprotective Agents pharmacology
Neuroprotective Agents therapeutic use
Neurotoxins antagonists & inhibitors
Neurotoxins metabolism
Neurotoxins toxicity
Organ Culture Techniques
Rats
Rats, Wistar
Receptors, N-Methyl-D-Aspartate metabolism
Vesicular Glutamate Transport Proteins metabolism
Glutamic Acid metabolism
Guanosine Monophosphate pharmacology
Hippocampus drug effects
N-Methylaspartate metabolism
Receptors, N-Methyl-D-Aspartate drug effects
Vesicular Glutamate Transport Proteins antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 0006-8993
- Volume :
- 1231
- Database :
- MEDLINE
- Journal :
- Brain research
- Publication Type :
- Academic Journal
- Accession number :
- 18655777
- Full Text :
- https://doi.org/10.1016/j.brainres.2008.07.009